Early phase trials of novel hearing therapeutics: Avenues and opportunities

Novel hearing therapeutics are rapidly progressing along the innovation pathway and into the clinical trial domain. Because these trials are new to the hearing community, they come with challenges in terms of trial design, regulation and delivery. In this paper, we address the key scientific and ope...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hearing research Ročník 380; s. 175 - 186
Hlavní autoři: Schilder, Anne G.M., Su, Matthew P., Mandavia, Rishi, Anderson, Caroline R., Landry, Evie, Ferdous, Tanjinah, Blackshaw, Helen
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 01.09.2019
Témata:
Aetiology
Auditory Perception - genetics
Clinical trial
Clinical Trials as Topic
Diagnosis
Diffusion of Innovation
Genetic Therapy
Genetics
Hearing
Hearing - genetics
Hearing Loss - genetics
Hearing Loss - physiopathology
Hearing Loss - psychology
Hearing Loss - rehabilitation
Humans
Persons with Hearing Disabilities - psychology
Persons with Hearing Disabilities - rehabilitation
Recovery of Function
Research Design
Stem Cell Transplantation
Therapeutics
Treatment Outcome
Genetics
Clinical trial
Hearing
Diagnosis
Aetiology
Therapeutics
ISSN:0378-5955, 1878-5891, 1878-5891
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Novel hearing therapeutics are rapidly progressing along the innovation pathway and into the clinical trial domain. Because these trials are new to the hearing community, they come with challenges in terms of trial design, regulation and delivery. In this paper, we address the key scientific and operational issues and outline the opportunities for interdisciplinary and international collaboration these trials offer. Vital to the future successful implementation of these therapeutics is to evaluate their potential for adoption into healthcare systems, including consideration of their health economic value. This requires early engagement with all stakeholder groups along the hearing innovation pathway. •Novel hearing loss therapies are rapidly progressing along the translational pathway.•To develop precision medicine for inner ear disorders, precision diagnosis is needed.•There is an urgent need for large-scale genotype–phenotype studies.•Clinical trials capability and capacity must increase in line with this growing field.•For implementation, it is vital to consider health economics and service impact.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0378-5955
1878-5891
1878-5891
DOI:10.1016/j.heares.2019.07.003